The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Can circulating tumor cell assessment by flow replace bone marrow aspirates to monitor SMM?
Featured:
Bruno PaivaVideo series
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Bruno Paiva, University of Navarra, Pamplona, ES. We asked, Can circulating tumor cell assessment by flow replace bone marrow aspirates to monitor smoldering multiple myeloma (SMM)?
Paiva talks about the iMMunocell study. The aims of this study are as follows:
1. To determine the level of concordance between the tumor/immune landscape in bone marrow versus peripheral blood of patients with SMM.
2. To evaluate immune profiles together with circulating tumor cell counts and genetic alterations every 6 months in peripheral blood, as minimally-invasive methods for identification of patients with SMM at risk of developing active disease.
Results from this study show a significant correlation between circulating tumor cell counts and stable versus progressive disease.
More from this series:
